Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Can-Fite Biopharma Ltd ADR (CANF)

Can-Fite Biopharma Ltd ADR (CANF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,384
  • Shares Outstanding, K 17,192
  • Annual Sales, $ 760 K
  • Annual Income, $ -14,440 K
  • 60-Month Beta 1.89
  • Price/Sales 47.09
  • Price/Cash Flow N/A
  • Price/Book 5.08
Trade CANF with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.12
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.15
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.95 +2.56%
on 07/27/21
2.37 -15.61%
on 07/14/21
-0.28 (-12.28%)
since 06/30/21
3-Month
1.94 +3.09%
on 05/11/21
2.62 -23.66%
on 06/15/21
-0.17 (-7.83%)
since 04/30/21
52-Week
1.51 +32.45%
on 09/04/20
4.39 -54.44%
on 03/16/21
-0.34 (-14.53%)
since 07/30/20

Most Recent Stories

More News
CORRECTION - Skyline Corporate Communications Group, LLC Launches its CEO Webinar Event the Skyline Signature Series

SKY : 56.40 (-0.91%)
CANF : 2.00 (-4.31%)
CFBI : 10.08 (-0.30%)
Aldeyra's (ALDX) ADX-2191 Gets Orphan Drug Tag for Rare Cancer

The FDA grants an Orphan Drug designation to Aldeyra's (ALDX) ADX-2191 for the treatment of primary vitreoretinal lymphoma.

CORT : 20.77 (+2.37%)
CANF : 2.00 (-4.31%)
ALDX : 8.90 (-1.33%)
FHTX : 9.07 (-3.51%)
Catalyst (CPRX) Thrives on Firdapse But Overdependence Concerns

Catalyst's (CPRX) Firdapse is approved for treating Lambert-Eaton myasthenic syndrome. The drug has seen solid uptake since its launch. Sole dependence on Firdapse for growth remains a concern.

CORT : 20.77 (+2.37%)
CPRX : 5.84 (+0.17%)
CANF : 2.00 (-4.31%)
CTLT : 119.81 (+0.41%)
Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 2.00 (-4.31%)
CFBI : 10.08 (-0.30%)
Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder Study

Savara (SVRA) is developing its lead pipeline candidate, molgramostim, as a potential treatment for autoimmune pulmonary alveolar proteinosis.

CANF : 2.00 (-4.31%)
XNCR : 30.78 (-3.18%)
SVRA : 1.2800 (unch)
ACER : 2.56 (-8.57%)
Jazz Pharma (JAZZ) Gets FDA Approval for Leukemia Drug Rylaze

Jazz Pharma (JAZZ) gets FDA approval for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.

JAZZ : 169.52 (-0.63%)
CANF : 2.00 (-4.31%)
XNCR : 30.78 (-3.18%)
ACER : 2.56 (-8.57%)
Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced...

CANF : 2.00 (-4.31%)
CFBI : 10.08 (-0.30%)
Can-Fite Receives Notice of Patent Allowance in China for NASH Treatment

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced...

CANF : 2.00 (-4.31%)
CFBI : 10.08 (-0.30%)
Thinking about buying stock in Torchlight Energy, Senseonics, Can Fite Biopharma, EHang Holdings, or Luckin Coffee?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRCH, SENS, CANF, EH, and LKNCY.

CANF : 2.00 (-4.31%)
SENS : 3.07 (+0.66%)
TRCH : 4.95 (+4.21%)
EH : 26.30 (+3.50%)
LKNCY : 12.4200 (-1.82%)
Skyline Corporate Communications Group, LLC Launches its CEO Webinar Event the Skyline Signature Series

SKY : 56.40 (-0.91%)
CANF : 2.00 (-4.31%)
CFBI : 10.08 (-0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Can Fite Biopharma Ltd. is a biopharmaceutical company. It is focused on developing drugs for the treatment of cancer and autoimmune inflammatory diseases. The Company's lead drug candidate, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. Its CF102 drug candidate...

See More

Key Turning Points

3rd Resistance Point 2.17
2nd Resistance Point 2.13
1st Resistance Point 2.07
Last Price 2.00
1st Support Level 1.97
2nd Support Level 1.93
3rd Support Level 1.87

See More

52-Week High 4.39
Fibonacci 61.8% 3.29
Fibonacci 50% 2.95
Fibonacci 38.2% 2.61
Last Price 2.00
52-Week Low 1.51

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar